ADGRA2: A Potential Approach To Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: ADGRA2

NCBI ID: G25960

ADGRA2

ADGRA2: A Potential Approach To Cancer, Neurodegenerative Diseases and Autoimmune Disorders

The Adhesion G protein-coupled receptor A2 (ADGRA2) is a transmembrane protein that plays a crucial role in cell-cell adhesion and tissue regeneration. It is a member of the G protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that regulate a wide range of cellular processes, including signaling, intracellular signaling, and cell-cell communication.

ADGRA2 is expressed in many different tissues and cells throughout the body, including the heart, kidneys, liver, and stem cells. It is involved in various physiological processes, including cell migration, cell survival, and tissue repair.

Drug targeting ADGRA2

ADGRA2 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main reasons for targeting ADGRA2 is its role in cancer progression. Many studies have shown that high levels of ADGRA2 are associated with poor prognosis in cancer patients. Additionally, research has suggested that ADGRA2 may play a role in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Another potential mechanism by which ADGRA2 may be targeted is its role in autoimmune disorders. Many autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, involve inflammation and the immune system. ADGRA2 has been shown to be involved in these processes, and may be a target for new treatments.

Targeting ADGRA2

There are several potential strategies that could be used to target ADGRA2. One approach is to use small molecules that can modulate the activity of ADGRA2. For example, inhibitors of the protein kinase CK5, which is a known activator of ADGRA2, have been shown to be effective in reducing the activity of ADGRA2.

Another approach is to use antibodies that can specifically bind to ADGRA2 and prevent it from interacting with its downstream signaling molecules. This approach is being used to target ADGRA2 in cancer and neurodegenerative diseases.

Another approach is to use gene editing techniques to modify the expression of ADGRA2. This approach can be used to introduce mutations that disrupt the activity of ADGRA2, or to knockdown the expression of ADGRA2 to reduce its levels.

Conclusion

ADGRA2 is a transmembrane protein that plays a crucial role in cell-cell adhesion and tissue regeneration. It is a member of the G protein-coupled receptor family and is involved in various physiological processes throughout the body. As a potential drug target, ADGRA2 is being targeted by researchers to study its role in cancer, neurodegenerative diseases, and autoimmune disorders.

Targeting ADGRA2 using small molecules, antibodies, or gene editing techniques may be effective in modulating its activity and have the potential to lead to new treatments for these diseases. Further research is needed to fully understand the role of ADGRA2 in these processes and to develop effective treatments.

Protein Name: Adhesion G Protein-coupled Receptor A2

Functions: Endothelial receptor which functions together with RECK to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B) (PubMed:28289266, PubMed:30026314). Plays a key role in Wnt7-specific responses, such as endothelial cell sprouting and migration in the forebrain and neural tube, and establishment of the blood-brain barrier (By similarity). Acts as a Wnt7-specific coactivator of canonical Wnt signaling: required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex (PubMed:30026314). ADGRA2-tethering function does not rely on its G-protein coupled receptor (GPCR) structure but instead on its combined capacity to interact with RECK extracellularly and recruit the Dishevelled scaffolding protein intracellularly (PubMed:30026314). Binds to the glycosaminoglycans heparin, heparin sulfate, chondroitin sulfate and dermatan sulfate (PubMed:16982628)

The "ADGRA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets